Noven acquires wide-ranging rights to Daytrana from Shire affiliates
Posted in Child Health on October 4th, 2010Noven Pharmaceuticals, Inc. today announced that it has completed the purchase of pandemic rights to Daytrana® (methylphenidate transdermal approach from affiliates of Shire plc ("Shire").
Daytrana was instance licensed globally to Shire particularly Noven in 2003 and was approved and launched in the U.S. in 2006. The consequence is indicated for the sake the treatment of Regard Loss Hyperactivity Upheaval ("ADHD") Read the rest of this entry »
